Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome
PHASE2CompletedINTERVENTIONAL
Enrollment
600
Participants
Timeline
Start Date
October 31, 2007
Primary Completion Date
April 30, 2009
Study Completion Date
August 31, 2009
Conditions
Acute Coronary Syndrome
Interventions
DRUG
E5555
DRUG
Placebo
Trial Locations (2)
53511-2230
Beloit Clinic, SC, Beloit
SW3 6NP
Royal Brompton Hospital, London
All Listed Sponsors
lead
Eisai Inc.
INDUSTRY
NCT00548587 - Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome | Biotech Hunter | Biotech Hunter